This suggests that assessing insulin resistance at baseline could help stratify patients likely to benefit from adjunctive therapies targeting insulin sensitivity to enhance rhGH responsiveness, as hyperinsulinemia is increasingly recognized as a key disruptor of the insulin-GH balance (19). This evidence concerns the gene GH1 and hyperinsulinism.